Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

Sajid Khan, PhD, Xuan Zhang, BMBS, Dongwen Lv, PhD, Yonghan He, MD, Peiyi Zhang, MS, Xingui Liu, PhD, Dinesh Thummuri, PhD, Qi Zhang, PhD, Marina Y. Konopleva, MD PhD, Robert A. Hromas, MD, Guangrong Zheng, Daohong Zhou, MD

Blood (2018) 132 (Supplement 1): 2698.

https://doi.org/10.1182/blood-2018-99-114762

Published: 2018

Journal Articles

miR-125b promotes MLL-AF9 –driven murine acute myeloid leukemia involving a VEGFA -mediated non–cell-intrinsic mechanism

Jun Liu, Bo Guo, Zhuo Chen, Nayi Wang, Michelina Iacovino, Jijun Cheng, Christine Roden, Wen Pan, Sajid Khan, Suning Chen, Michael Kyba, Rong Fan, Shangqin Guo, Jun Lu

Blood (2017) 129 (11): 1491–1502.

https://doi.org/10.1182/blood-2016-06-721027

Published: 2017

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

miR-125b promotes MLL-AF9 –driven murine acute myeloid leukemia involving a VEGFA -mediated non–cell-intrinsic mechanism

Email alerts

ASH Publications

American Society of Hematology

Update search

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

miR-125b promotes MLL-AF9 –driven murine acute myeloid leukemia involving a VEGFA -mediated non–cell-intrinsic mechanism

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only